Prurigo Nodularis
42
6
13
22
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
17 trials with published results (40%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
7.1%
3 terminated out of 42 trials
88.0%
+1.5% vs benchmark
38%
16 trials in Phase 3/4
77%
17 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (42)
A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
Study on the Treatment of Prurigo Nodularis With Stapokibart Injection
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
Upadacitinib for Prurigo Nodularis
Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
A Study of Barzolvolimab in Patients With Prurigo Nodularis
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
Effect of EMD Protocol for Urge on Dermatology-specific Quality of Life
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
Determinants of Chronic Inflammatory Skin Disease Trajectories
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
PRISM Study-Pruritus Relief Through Itch Scratch Modulation